

**REMARKS**

Claim 10 has been amended to replace the term “compound” with “tubulin inhibitor” in response to the kind suggestion of Examiner Willis in the above mentioned telephone conference. Since the compounds in the cited document that putatively render the compounds of claim 10 obvious are disclosed as insulin secretion accelerators, not as tubulin inhibitors, this distinction was suggested by the Examiner to be included in the claims. Accordingly, claim 10 was amended to be limited to tubulin inhibitors. In accordance with this amendment, claim 14 and claim 23, which were also rejected, have corresponding amendments. It is believed that this amendment, then, places these claims in a position for allowance.

Claim 11 was merely objected to as dependent on claim 10. This has now been removed and thus claim 11 is clearly in a position for allowance as well as claim 21 dependent thereon.

Claim 24 was indicated as having allowable subject matter but objected to as dependent on an unallowed claim. Claim 24 has now been made independent and is thus in a position for allowance as are claims 25 and 27-28 dependent thereon.

Claims 28 and 30 were indicated as allowable.

Thus, in summary, claim 10 and claims 14 and 23 dependent thereon have been amended to be restricted to tubulin inhibitors and should be in a position for allowance. Claim 11 has been amended to place it in independent form and is thus allowable along with claim 21 dependent on it. Claim 12 and its dependent claim 22 are already allowed. Claim 24 has been amended to place it in independent form and is thus allowable along with the claims dependent thereon, claims 25, 27 and 28. Claims 29 and 30 were allowed.

The informality in claim 10 has also been corrected.

Should additional issues arise with respect to rejoinder of these claims, a telephone call to the undersigned is respectfully requested to discuss the possibility of amendment or cancellation of these claims.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 415852000200.

By: \_\_\_\_\_ / Kate H. Murashige /  
 Kate H. Murashige  
 Registration No.: 29,959  
 MORRISON & FOERSTER LLP  
 12531 High Bluff Drive, Suite 100  
 San Diego, California 92130-2040  
 Telephone: (858) 720-5112  
 Facsimile: (858) 720-5125